CU23105A3 - DERIVADOS NOVEDOSOS DEL áCIDO AMINODICARBOXILICO CON PROPIEDADES FARMACéUTICAS - Google Patents

DERIVADOS NOVEDOSOS DEL áCIDO AMINODICARBOXILICO CON PROPIEDADES FARMACéUTICAS

Info

Publication number
CU23105A3
CU23105A3 CU32A CU20020032A CU23105A3 CU 23105 A3 CU23105 A3 CU 23105A3 CU 32 A CU32 A CU 32A CU 20020032 A CU20020032 A CU 20020032A CU 23105 A3 CU23105 A3 CU 23105A3
Authority
CU
Cuba
Prior art keywords
aminodicarboxilic
novedous
derivatives
acid
pharmaceutical properties
Prior art date
Application number
CU32A
Other languages
English (en)
Inventor
Frank Wunder
Joseph Pernerstorfer
Dietmar Flubacher
Markus Heil
Elke Stahl
Johannes-Peter Stasch
Cristina Alonso-Alija
Paul Naab
Elisabeth Perzborn
Klaus Dembowsky
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of CU23105A3 publication Critical patent/CU23105A3/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/30—Halogen atoms or nitro radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/38—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to acyclic carbon atoms and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/24—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/25—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/56—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/12—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/54—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and etherified hydroxy groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
    • C07C275/20—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
    • C07C275/24—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C317/18—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/10—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C323/18—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C07C323/19—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton with singly-bound oxygen atoms bound to acyclic carbon atoms of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/38—One sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/06—1,2,3-Thiadiazoles; Hydrogenated 1,2,3-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/16—Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invencion se refiere al uso de compuestos de formula (I), así como a sus sales y estereoisomeros, para la preparacion de medicamentos para el tratamiento de enfermedades cardiovasculares.
CU32A 1999-09-13 2002-02-13 DERIVADOS NOVEDOSOS DEL áCIDO AMINODICARBOXILICO CON PROPIEDADES FARMACéUTICAS CU23105A3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19943635A DE19943635A1 (de) 1999-09-13 1999-09-13 Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften

Publications (1)

Publication Number Publication Date
CU23105A3 true CU23105A3 (es) 2006-01-20

Family

ID=7921724

Family Applications (1)

Application Number Title Priority Date Filing Date
CU32A CU23105A3 (es) 1999-09-13 2002-02-13 DERIVADOS NOVEDOSOS DEL áCIDO AMINODICARBOXILICO CON PROPIEDADES FARMACéUTICAS

Country Status (39)

Country Link
US (4) US7087644B1 (es)
EP (1) EP1216225B1 (es)
JP (2) JP4456312B2 (es)
KR (1) KR100715380B1 (es)
CN (1) CN100390135C (es)
AR (1) AR033346A1 (es)
AT (1) ATE299134T1 (es)
AU (1) AU767750B2 (es)
BG (1) BG65834B1 (es)
BR (1) BR0014179A (es)
CA (1) CA2387107C (es)
CO (1) CO5221052A1 (es)
CU (1) CU23105A3 (es)
CZ (1) CZ302250B6 (es)
DE (2) DE19943635A1 (es)
DK (1) DK1216225T3 (es)
EE (1) EE05194B1 (es)
ES (1) ES2244466T3 (es)
HK (1) HK1053638B (es)
HR (1) HRP20020307B1 (es)
HU (1) HUP0203418A3 (es)
IL (2) IL148134A0 (es)
MA (1) MA25875A1 (es)
MX (1) MXPA02002651A (es)
MY (1) MY128659A (es)
NO (1) NO327998B1 (es)
NZ (1) NZ517709A (es)
PE (1) PE20010637A1 (es)
PL (1) PL206256B1 (es)
PT (1) PT1216225E (es)
RU (1) RU2280025C9 (es)
SK (1) SK287368B6 (es)
SV (1) SV2002000169A (es)
TR (1) TR200200649T2 (es)
TW (1) TWI225045B (es)
UA (1) UA74346C2 (es)
UY (1) UY26332A1 (es)
WO (1) WO2001019780A2 (es)
ZA (1) ZA200201299B (es)

Families Citing this family (236)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6414002B1 (en) * 1999-09-22 2002-07-02 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
DE10109858A1 (de) * 2001-03-01 2002-09-05 Bayer Ag Neuartige halogensubstituierte Aminodicarbonsäurederivate
DE10109859A1 (de) * 2001-03-01 2002-09-05 Bayer Ag Neuartige Aminodicarbonsäurederivate
DE10109861A1 (de) * 2001-03-01 2002-09-05 Bayer Ag Neuartige seitenkettenhalogenierte Aminodicarbonsäurederivate
DE10110747A1 (de) * 2001-03-07 2002-09-12 Bayer Ag Substituierte 2,6-Diamino-3,5-dicyano-4-aryl-pyridine und ihre Verwendung
DE10110749A1 (de) * 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
DE10121003A1 (de) 2001-04-28 2002-12-19 Aventis Pharma Gmbh Anthranilsäureamide, Verfahren zur Herstellung, ihrer Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
DE10257357A1 (de) 2002-12-09 2004-06-24 Bayer Ag Fluorhaltige Benzaldehyde
DE10257356A1 (de) * 2002-12-09 2004-06-24 Bayer Ag Fluorhaltige Aromaten
DE102004042607A1 (de) * 2004-09-03 2006-03-09 Bayer Healthcare Ag Substituierte Phenylaminothiazole und ihre Verwendung
CA2583073A1 (en) * 2004-10-05 2006-04-13 Bayer Healthcare Ag A guanylane cyclase stimulator and nitric oxide for treating bronchoconstriction and pulmonary vasoconstriction
DE102005031575A1 (de) * 2005-07-06 2007-01-11 Bayer Healthcare Ag Verwendung von Aktivatoren der löslichen Guanylatzyklase zur Förderung der Wundheilung
DE102005031576A1 (de) * 2005-07-06 2007-01-25 Bayer Healthcare Ag Verwendung von Aktivatoren der löslichen Guanylatzyklase zur Behandlung von Reperfusionsschäden
DE102005047945A1 (de) * 2005-07-16 2007-01-18 Bayer Healthcare Ag Verwendung von Aktivatoren der löslichen Guanylatzyklase zur Behandlung von Raynaud Phänomenen
MX2008000779A (es) * 2005-07-18 2008-02-21 Bayer Healthcare Ag Uso de activadores y estimuladores de guanilatociclasa solubles para la prevencion o tratamiento de trastornos renales.
DE102005047946A1 (de) * 2005-10-06 2007-05-03 Bayer Healthcare Ag Verwendung von Aktivatoren der löslichen Guanylatzyklase zur Behandlung von akuten und chronischen Lungenkrankheiten
DE102005050498A1 (de) * 2005-10-21 2007-06-06 Bayer Healthcare Aktiengesellschaft Cyclopropylessigsäure-Derivate und ihre Verwendung
DE102005050376A1 (de) * 2005-10-21 2007-05-31 Bayer Healthcare Ag Dicarbonsäure-Derivate und ihre Verwendung
DE102005050497A1 (de) * 2005-10-21 2007-04-26 Bayer Healthcare Ag Difluorphenol-Derivate und ihre Verwendung
DE102005050377A1 (de) * 2005-10-21 2007-04-26 Bayer Healthcare Ag Heterocyclische Verbindungen und ihre Verwendung
DE102005050375A1 (de) * 2005-10-21 2007-04-26 Bayer Healthcare Ag Tetrazol-Derivate und ihre Verwendung
DE102006024024A1 (de) 2006-05-23 2007-11-29 Bayer Healthcare Aktiengesellschaft Substituierte Arylimidazolone und -triazolone sowie ihre Verwendung
DE102006042143A1 (de) * 2006-09-08 2008-03-27 Bayer Healthcare Aktiengesellschaft Neue substituierte Bipyridin-Derivate und ihre Verwendung
DE102006044696A1 (de) * 2006-09-22 2008-03-27 Bayer Healthcare Ag 3-Cyano-5-thiazaheteroaryl-dihydropyridine und ihre Verwendung
DE102006056739A1 (de) * 2006-12-01 2008-06-05 Bayer Healthcare Ag Substituierte 4-Amino-3,5-dicyano-2-thiopyridine und ihre Verwendung
DE102006056740A1 (de) * 2006-12-01 2008-06-05 Bayer Healthcare Ag Cyclisch substituierte 3,5-Dicyano-2-thiopyridine und ihre Verwendung
DE102007009494A1 (de) 2007-02-27 2008-08-28 Bayer Healthcare Ag Substituierte 4-Aryl-1, 4-dihydro-1,6-naphthyridinamide und ihre Verwendung
DE102007015034A1 (de) * 2007-03-29 2008-10-02 Bayer Healthcare Ag Lactam-substituierte Dicarbonsäuren und ihre Verwendung
DE102007015035A1 (de) 2007-03-29 2008-10-02 Bayer Healthcare Ag Substituierte Dibenzoesäure-Derivate und ihre Verwendung
DE102007019690A1 (de) 2007-04-26 2008-10-30 Bayer Healthcare Ag Verwendung von cyclisch substituierten Furopyrimidin-Derivaten zur Behandlung der pulmonalen arteriellen Hypertonie
DE102007019691A1 (de) 2007-04-26 2008-10-30 Bayer Healthcare Ag Verwendung von acyclisch substituierten Furopyrimidin-Derivaten zur Behandlung der pulmonalen arteriellen Hypertonie
DE102007026392A1 (de) 2007-06-06 2008-12-11 Bayer Healthcare Ag Lösungen für die Perfusion und Konservierung von Organen und Geweben
DE102007027800A1 (de) 2007-06-16 2008-12-18 Bayer Healthcare Ag Substituierte bicyclische Heteroaryl-Verbindungen und ihre Verwendung
DE102007027799A1 (de) 2007-06-16 2008-12-18 Bayer Healthcare Ag Substituierte Furopyrimidine und ihre Verwendung
DE102007028319A1 (de) 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102007028406A1 (de) 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102007028320A1 (de) 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102007028407A1 (de) 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102007035367A1 (de) 2007-07-27 2009-01-29 Bayer Healthcare Ag Substituierte Aryloxazole und ihre Verwendung
DE102007036076A1 (de) 2007-08-01 2009-02-05 Bayer Healthcare Aktiengesellschaft Dipeptoid-Produgs und ihre Verwendung
DE102007042754A1 (de) 2007-09-07 2009-03-12 Bayer Healthcare Ag Substituierte 6-Phenylnikotinsäuren und ihre Verwendung
DE102007051762A1 (de) 2007-10-30 2009-05-07 Bayer Healthcare Ag Substituierte Pyrrolotriazine und ihre Verwendung
DE102007054786A1 (de) 2007-11-16 2009-05-20 Bayer Healthcare Ag Trisubstituierte Furopyrimidine und ihre Verwendung
DE102007061764A1 (de) 2007-12-20 2009-06-25 Bayer Healthcare Ag Anellierte Cyanopyridine und ihre Verwendung
DE102008052013A1 (de) 2008-10-17 2010-04-22 Bayer Schering Pharma Aktiengesellschaft 4-(4-Cyano-2-thioaryl)-dihydropyrimidinone und ihre Verwendung
DE102007061766A1 (de) 2007-12-20 2009-06-25 Bayer Healthcare Ag 4-(4-Cyano-2-thioaryl)-dihydropyrimidinone und ihre Verwendung
DE102007061757A1 (de) 2007-12-20 2009-06-25 Bayer Healthcare Ag Substituierte 2-Phenylpyrimidin-5-carbonsäuren und ihre Verwendung
DE102007061763A1 (de) * 2007-12-20 2009-06-25 Bayer Healthcare Ag Substituierte azabicyclische Verbindungen und ihre Verwendung
DE102008022521A1 (de) 2008-05-07 2009-11-12 Bayer Schering Pharma Aktiengesellschaft 1,4-Diaryl-pyrimidopyridazin-2,5-dione und ihre Verwendung
DE102007061756A1 (de) 2007-12-20 2009-06-25 Bayer Healthcare Ag Substituierte 4-Aminopyrimidin-5-carbonsäuren und ihre Verwendung
DE102008007400A1 (de) 2008-02-04 2009-08-06 Bayer Healthcare Ag Substituierte Furane und ihre Verwendung
DE102008013587A1 (de) 2008-03-11 2009-09-17 Bayer Schering Pharma Aktiengesellschaft Heteroaryl-substituierte Dicyanopyridine und ihre Verwendung
US8461348B2 (en) * 2008-04-04 2013-06-11 Takeda Pharmaceutical Company Limited Heterocyclic derivative and use thereof
RU2010150451A (ru) * 2008-05-10 2012-06-20 Байер Шеринг Фарма Акциенгезельшафт (DE) Стимуляторы ргц и их комбинации для лечения нарушения слуха
JP2011520997A (ja) * 2008-05-29 2011-07-21 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト ２−アルコキシ置換ジシアノピリジン類およびそれらの使用
DE102008030207A1 (de) 2008-06-25 2009-12-31 Bayer Schering Pharma Aktiengesellschaft Substituierte 7-Sulfanylmethyl-, 7-Sulfinylmethyl- und 7-Sulfonylmethyl-Indole und ihre Verwendung
DE102008030206A1 (de) 2008-06-25 2009-12-31 Bayer Schering Pharma Aktiengesellschaft 3-Cyanoalky- und 3-Hydroxyalkyl-Indole und ihre Verwendung
EP2138178A1 (en) 2008-06-28 2009-12-30 Bayer Schering Pharma Aktiengesellschaft Oxazolidninones for the treatment fo chronic obstructive pulmonary disease (COPD) and/or asthma
DE102008039082A1 (de) 2008-08-21 2010-02-25 Bayer Schering Pharma Aktiengesellschaft Azabicyclisch-substituierte 5-Aminopyrazole und ihre Verwendung
DE102008039083A1 (de) 2008-08-21 2010-02-25 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Aminopyrazole und ihre Verwendung
DE102008054205A1 (de) 2008-10-31 2010-05-06 Bayer Schering Pharma Aktiengesellschaft Verwendung von Helium-Sauerstoff-Gasgemischen zur Behandlung der pulmonalen arteriellen Hypertonie
DE102008060967A1 (de) 2008-12-06 2010-06-10 Bayer Schering Pharma Aktiengesellschaft Substituierte Phenylsulfonyltriazolone und ihre Verwendung
DE102008062567A1 (de) 2008-12-16 2010-06-17 Bayer Schering Pharma Aktiengesellschaft Dipeptoid-Prodrugs und ihre Verwendung
DE102008062566A1 (de) 2008-12-16 2010-06-17 Bayer Schering Pharma Aktiengesellschaft Aminosäureester-Prodrugs und ihre Verwendung
DE102008062688A1 (de) * 2008-12-17 2010-06-24 Bayer Schering Pharma Aktiengesellschaft Monohydrat der 4-({(4-Carboxybutyl)[2-(2-{[4-(2-phenylethyl)benzyl]oxy}phenyl)ethyl]-amino}methyl)benzoesäure
DE102008062689A1 (de) 2008-12-17 2010-06-24 Bayer Schering Pharma Aktiengesellschaft Modifikation I der 4-({(4-Carboxybutyl)[2-(2-{[4-(2-phenylethyl)benzyl]oxy}phenyl)ethyl]-amino}methyl)benzoesäure
DE102009004197A1 (de) 2009-01-09 2010-07-15 Bayer Schering Pharma Aktiengesellschaft Heterocyclisch anellierte Diaryldihydropyrimidin-Derivate und ihre Verwendung
EA201170942A1 (ru) 2009-01-17 2012-02-28 Байер Фарма Акциенгезельшафт СТИМУЛЯТОРЫ рГЦ ИЛИ АКТИВАТОРЫ рГЦ В КОМБИНАЦИИ С ИНГИБИТОРАМИ ФДЭ5 ДЛЯ ЛЕЧЕНИЯ ЭРЕКТИЛЬНОЙ ДИСФУНКЦИИ
DE102009006602A1 (de) * 2009-01-29 2010-08-05 Bayer Schering Pharma Aktiengesellschaft Alkylamino-substituierte Dicyanopyridine und deren Aminosäureester-Prodrugs
DE102010001064A1 (de) 2009-03-18 2010-09-23 Bayer Schering Pharma Aktiengesellschaft Substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung
DE102009013642A1 (de) 2009-03-18 2010-09-23 Bayer Schering Pharma Aktiengesellschaft Substituierte Phenylalaninderivate und deren Verwendung
DE102009016553A1 (de) 2009-04-06 2010-10-07 Bayer Schering Pharma Aktiengesellschaft Sulfonamid- und Sulfoximin-substituierte Diaryldihydropyrimidinone und ihre Verwendung
DE102009028929A1 (de) 2009-08-27 2011-07-07 Bayer Schering Pharma Aktiengesellschaft, 13353 Heterocyclisch-substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung
AU2011212521B2 (en) 2010-02-05 2015-11-19 Adverio Pharma Gmbh sGC stimulators or sGC activators alone and in combination with PDE5 inhbitors for the treatment of Cystic Fibrosis
WO2011095553A1 (en) 2010-02-05 2011-08-11 Bayer Schering Pharma Aktiengesellschaft Sgc stimulators or sgc activators in combination with pde5 inhbitors for the treatment of erectile dysfunction
AU2011219746B2 (en) 2010-02-27 2015-04-23 Bayer Intellectual Property Gmbh Bisaryl-bonded aryltriazolones and use thereof
US20130178475A1 (en) 2010-03-17 2013-07-11 Ironwood Pharmaceuticals, Inc. sGC STIMULATORS
DE102010020553A1 (de) 2010-05-14 2011-11-17 Bayer Schering Pharma Aktiengesellschaft Substituierte 8-Alkoxy-2-aminotetralin-Derivate und ihre Verwendung
AU2011257336B2 (en) * 2010-05-26 2015-11-19 Adverio Pharma Gmbh The use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc).
DE102010030187A1 (de) 2010-06-16 2011-12-22 Bayer Schering Pharma Aktiengesellschaft 4-Cyan-2-sulfonylphenyl)pyrazolyl-substituierte Pyridinone und Pyrazinone und ihre Verwendung
US20130158028A1 (en) 2010-06-25 2013-06-20 Bayer Intellectual Property Gmbh Use of stimulators and activators of soluble guanylate cyclase for treating sickle-cell anemia and conserving blood substitutes
EA026692B1 (ru) 2010-06-30 2017-05-31 Айронвуд Фармасьютикелз, Инк. Стимуляторы sgc
DE102010030688A1 (de) 2010-06-30 2012-01-05 Bayer Schering Pharma Aktiengesellschaft Substituierte Dicyanopyridine und ihre Verwendung
MA34373B1 (fr) 2010-07-14 2013-07-03 Novartis Ag Composés hétérocycliques agonistes du récepteur ip
US20120058983A1 (en) 2010-09-02 2012-03-08 Bayer Pharma Aktiengesellschaft Adenosine A1 agonists for the treatment of glaucoma and ocular hypertension
DE102010040187A1 (de) 2010-09-02 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Substituierte N-Phenethyl-triazolonacetamide und ihre Verwendung
DE102010040924A1 (de) 2010-09-16 2012-03-22 Bayer Schering Pharma Aktiengesellschaft Substituierte Phenylacet- und Phenylpropanamide und ihre Verwendung
WO2012064559A1 (en) 2010-11-09 2012-05-18 Ironwood Pharmaceuticals, Inc. Sgc stimulators
RU2014103288A (ru) 2011-07-01 2015-08-10 Байер Интеллектчуал Проперти Гмбх Слитые полипептиды релаксина и их применение
KR20140039257A (ko) 2011-07-08 2014-04-01 바이엘 인텔렉쳐 프로퍼티 게엠베하 릴랙신을 방출하는 융합 단백질 및 이의 용도
US8883819B2 (en) 2011-09-01 2014-11-11 Irm Llc Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
EP2797915B1 (en) 2011-12-27 2016-07-13 Ironwood Pharmaceuticals, Inc. 2-benzyl-3-(oxazole/thiazole)-5-(pyrimidin-2-yl)-1(H)-pyrazole derivatives as stimulators of the soluble guanylate cyclase (sGC) for the treatment of e.g. hypertension or heart failure
WO2013105065A1 (en) 2012-01-13 2013-07-18 Novartis Ag Fused piperidines as ip receptor agonists for the treatment of pah and related disorders
US20150005311A1 (en) 2012-01-13 2015-01-01 Novartis Ag IP receptor agonist heterocyclic compounds
WO2013105061A1 (en) 2012-01-13 2013-07-18 Novartis Ag Fused dihydropyrido [2,3 -b] pyrazines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders
US20140378463A1 (en) 2012-01-13 2014-12-25 Novartis Ag IP receptor agonist heterocyclic compounds
ES2565826T3 (es) 2012-01-13 2016-04-07 Novartis Ag Pirroles fusionados como agonistas del receptor IP para el tratamiento de hipertensión arterial pulmonar (PAH) y trastornos relacionados
JP6058698B2 (ja) 2012-01-13 2017-01-11 ノバルティス アーゲー Ｉｐ受容体アゴニストの塩
WO2013144191A1 (de) 2012-03-29 2013-10-03 Bayer Intellectual Property Gmbh Substituierte 2 -amino - 3 - cyanopyridine als inhibitoren des natrium calcium austausches und ihre verwendung bei kardiovaskulären erkrankungen
JP6118965B2 (ja) 2012-04-16 2017-04-26 トーアエイヨー株式会社 ２環性化合物
UA112897C2 (uk) 2012-05-09 2016-11-10 Байєр Фарма Акцієнгезелльшафт Біциклічно заміщені урацили та їх застосування для лікування і/або профілактики захворювань
EP2847228B1 (en) 2012-05-10 2018-07-25 Bayer Pharma Aktiengesellschaft Antibodies capable of binding to the coagulation factor xi and/or its activated form factor xia and uses thereof
BR112015001211B1 (pt) 2012-07-20 2020-12-15 Bayer Pharma Aktiengesellschaft Ácidos 5-aminotetra-hidroquinolina-2-carboxílicos, processos para a sua preparação, seus usos no tratamento e/ou prevenção de doenças e seus medicamentos
WO2014012935A1 (de) 2012-07-20 2014-01-23 Bayer Pharma Aktiengesellschaft Substituierte aminoindan- und aminotetralin-carbonsäuren und ihre verwendung
WO2014047111A1 (en) 2012-09-18 2014-03-27 Ironwood Pharmaceuticals, Inc. Sgc stimulators
CA2885645A1 (en) 2012-09-19 2014-03-27 Ironwood Pharmaceuticals, Inc. Sgc stimulators
US9604981B2 (en) 2013-02-13 2017-03-28 Novartis Ag IP receptor agonist heterocyclic compounds
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
RS63108B1 (sr) 2013-03-15 2022-04-29 Cyclerion Therapeutics Inc Sgc stimulatori
US10265314B2 (en) 2013-07-25 2019-04-23 Bayer Pharma Aktiengesellschaft SGC stimulators in combination with additional treatment for the therapy of cystic fibrosis
EP3492106B1 (en) 2013-08-09 2021-02-17 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
US20160221965A1 (en) 2013-09-16 2016-08-04 Bayer Pharma Aktiengesellschaft Disubstituted trifluoromethyl pyrimidinones and their use
TN2016000121A1 (en) 2013-10-07 2017-10-06 Bayer Pharma AG Cyclic thienouracil-carboxamides and use thereof
EP3059224B1 (en) * 2013-10-15 2019-03-20 TOA Eiyo Ltd. 4-aminomethylbenzoic acid derivative
US20160256460A1 (en) 2013-11-01 2016-09-08 Bergen Teknologioverføring As Activators or stimulators of soluble guanylate cyclase for use in treating chronic fatigue syndrome
JP2016536362A (ja) 2013-11-08 2016-11-24 バイエル ファーマ アクチエンゲゼルシャフト 置換されているウラシル類及びそれらの使用
HK1224288A1 (zh) 2013-11-08 2017-08-18 Bayer Pharma Aktiengesellschaft 作为类糜蛋白酶抑制剂的取代的尿嘧啶
US20160311826A1 (en) 2013-12-11 2016-10-27 Ironwood Pharmaceuticals, Inc. Sgc stimulators
WO2015091420A1 (de) 2013-12-19 2015-06-25 Bayer Pharma Aktiengesellschaft Substituierte bipiperidinyl-derivate als adrenrezeptor alpha 2c antagonisten
JP2017501164A (ja) 2013-12-19 2017-01-12 バイエル ファーマ アクチエンゲゼルシャフト 置換されたピペリジニルテトラヒドロキノリン類
WO2015091415A1 (de) 2013-12-19 2015-06-25 Bayer Pharma Aktiengesellschaft Substituierte bipiperidinyl-derivate als adrenorezeptor alpha 2c antagonisten
WO2015091414A2 (de) 2013-12-19 2015-06-25 Bayer Pharma Aktiengesellschaft Substituierte piperidinyl-tetrahydrochinoline
EP3094327A1 (en) 2014-01-13 2016-11-23 Ironwood Pharmaceuticals, Inc. USE OF sGC STIMULATORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS
CN106661008A (zh) 2014-04-03 2017-05-10 拜耳制药股份公司 用于治疗呼吸道疾病的2,5‑二取代的环戊烷甲酸
WO2015150363A1 (de) 2014-04-03 2015-10-08 Bayer Pharma Aktiengesellschaft 2,5-disubstituierte cyclopentancarbonsäuren und ihre verwendung
US20170119776A1 (en) 2014-04-03 2017-05-04 Bayer Pharma Aktiengesellschaft Chiral 2,5-disubstituted cyclopentanecarboxylic acid derivatives and use thereof
CN106458980A (zh) 2014-04-24 2017-02-22 诺华股份有限公司 作为磷脂酰肌醇3‑激酶抑制剂的氨基吡啶衍生物
BR112016024533A8 (pt) 2014-04-24 2021-03-30 Novartis Ag derivados de amino pirazina como inibidores de fosfatidilinositol 3-cinase ou sal, seu uso, e composição e combinação farmacêuticas
KR20160141856A (ko) 2014-04-24 2016-12-09 노파르티스 아게 포스파티딜이노시톨 3-키나제 억제제로서의 피라진 유도체
CN116655627A (zh) 2014-08-01 2023-08-29 拜耳医药股份有限公司 一种化合物的制备方法及其纯化以用作活性药物成分
CN107074773A (zh) 2014-09-09 2017-08-18 拜耳制药股份公司 取代的n,2‑二芳基喹啉‑4‑甲酰胺及其用途
US20170291889A1 (en) 2014-09-17 2017-10-12 Ironwood Pharmaceuticals, Inc. Pyrazole derivatives as sgc stimulators
US20170298055A1 (en) 2014-09-17 2017-10-19 Ironwood Pharmaceuticals, Inc. sGC STIMULATORS
MX2017003518A (es) 2014-09-17 2017-07-28 Ironwood Pharmaceuticals Inc Estimuladores de guanilato ciclasa soluble (sgc).
ES2712886T3 (es) 2014-09-24 2019-05-16 Bayer Pharma AG Derivados de piridobenzazepina y piridobenzazocina que inhiben el factor XIa
EA032137B1 (ru) 2014-11-03 2019-04-30 Байер Фарма Акциенгезельшафт Производные гидроксиалкил-замещенного фенилтриазола и их применение
WO2016113205A1 (de) 2015-01-13 2016-07-21 Bayer Pharma Aktiengesellschaft Substituierte pentafluorethylpyrimidinone und ihre verwendung
UY36586A (es) 2015-03-26 2016-10-31 Bayer Pharma AG Heterociclilmetiltienouracilos y uso de los mismos
US20180169095A1 (en) 2015-05-06 2018-06-21 Bayer Pharma Aktiengesellschaft The use of sgc stimulators, sgc activators, alone and combinations with pde5 inhibitors for the treatment of digital ulcers (du) concomitant to systemic sclerosis (ssc)
CN113750102A (zh) 2015-07-23 2021-12-07 拜耳制药股份公司 可溶性鸟苷酸环化酶的刺激剂和/或活化剂及其用途
PT3337800T (pt) 2015-08-21 2019-08-05 Bayer Pharma AG Método para a preparação de (4s)-4-(4-ciano-2-metoxi fenil)-5-etoxi-2,8-dimetil-1,4-di-hidro-1-6-naftiridina-3- carboxamida e purificação do mesmo para a utilização como ingrediente farmacêutico ativo
WO2017081044A1 (en) 2015-11-13 2017-05-18 Bayer Pharma Aktiengesellschaft 4-(4-cyano-2-thioaryl)dihydropyrimidinones for treating chronic wounds
WO2017097671A1 (de) 2015-12-10 2017-06-15 Bayer Pharma Aktiengesellschaft Substituierte perhydropyrrolo[3,4-c]pyrrol-derivate und ihre verwendung
KR20180088462A (ko) 2015-12-10 2018-08-03 바이엘 파마 악티엔게젤샤프트 수면-관련 호흡기 장애의 치료를 위한 TASK-1 및 TASK-2 채널의 차단제로서의 2-페닐-3-(피페라지노메틸)이미다조[1,2-a]피리딘 유도체
CA3006764A1 (en) 2015-12-14 2017-06-22 Ironwood Pharmaceuticals, Inc. Use of sgc stimulators for the treatment of gastrointestinal sphincter dysfunction
WO2017153235A1 (de) 2016-03-09 2017-09-14 Bayer Pharma Aktiengesellschaft Substituierte n-cyclo-3-aryl-1-naphthamide und ihre verwendung
WO2017153234A1 (de) 2016-03-09 2017-09-14 Bayer Pharma Aktiengesellschaft Substituierte n-cyclo-2-arylchinolin-4-carboxamide und ihre verwendung
WO2017153231A1 (de) 2016-03-09 2017-09-14 Bayer Pharma Aktiengesellschaft Substituierte n-cyclo-2-arylisochinolinon-4-carboxamide und ihre verwendung
WO2017191112A1 (en) 2016-05-03 2017-11-09 Bayer Pharma Aktiengesellschaft Fluoroalkyl-substituted aryltriazole derivatives and uses thereof
US10815205B2 (en) 2016-05-03 2020-10-27 Bayer Pharma Aktiengesellschaft Amide-substituted phenyltriazole derivatives and uses thereof
US9988367B2 (en) 2016-05-03 2018-06-05 Bayer Pharma Aktiengesellschaft Amide-substituted pyridinyltriazole derivatives and uses thereof
CN109071464A (zh) 2016-05-03 2018-12-21 拜耳制药股份公司 氧代烷基取代的苯基三唑衍生物及其用途
EP3452472A1 (en) 2016-05-03 2019-03-13 Bayer Aktiengesellschaft Hydroxyalkyl-substituted heteroaryltriazole derivatives and uses thereof
WO2017191105A1 (en) 2016-05-03 2017-11-09 Bayer Pharma Aktiengesellschaft Amide-substituted aryltriazole derivatives and uses thereof
WO2017191117A1 (en) 2016-05-03 2017-11-09 Bayer Pharma Aktiengesellschaft V1a receptor antagonists for use in the treatment of renal diseases
JOP20170113B1 (ar) 2016-05-09 2023-03-28 Bayer Pharma AG مركبات 5، 6، 7، 8-رباعي هيدرو [1، 2، 4] تريازولو [4، 3-أ] بيريدين 3(2h)-ون مستبدلة ومركبات 2، 5، 6، 7-رباعي هيدرو-3h-بيرولو [2، 1-ج] [1، 2، 4] تريازول-3-ون واستخداماتها
JP2019524710A (ja) 2016-07-07 2019-09-05 アイアンウッド ファーマシューティカルズ インコーポレイテッド Ｓｇｃ刺激剤の固体形態
MA45592A (fr) 2016-07-07 2019-05-15 Ironwood Pharmaceuticals Inc Promédicaments à base de phosphore de stimulateurs de sgc
CA3030204A1 (en) 2016-07-11 2018-01-18 Bayer Pharma Aktiengesellschaft 7-substituted 1-pyridyl-naphthyridine-3-carboxylic acid amides and use thereof
JOP20190005A1 (ar) 2016-07-20 2019-01-20 Bayer Ag مركبات ديازاهيترو ثنائية الحلقة مستبدلة واستخداماتها
MY199759A (en) 2016-09-02 2023-11-21 Tisento Therapeutics Inc Fused bicyclic sgc stimulators
WO2018041771A1 (de) 2016-09-02 2018-03-08 Bayer Pharma Aktiengesellschaft (1-methylcyclopropyl)methyl-substituierte thienouracile und ihre verwendung
EP3296298A1 (de) 2016-09-14 2018-03-21 Bayer Pharma Aktiengesellschaft 7-substituierte 1-aryl-naphthyridin-3-carbonsäureamide und ihre verwendung
JOP20190045A1 (ar) 2016-09-14 2019-03-14 Bayer Ag مركبات أميد حمض 1- أريل-نفثيريدين-3-كربوكسيليك مستبدلة في الموضع 7 واستخدامها.
SG11201902588PA (en) 2016-09-23 2019-05-30 Bayer Ag N3-Cyclically Substituted Thienouracils And Use Thereof
CN109890379A (zh) 2016-10-11 2019-06-14 拜耳制药股份公司 包含sGC活化剂和盐皮质激素受体拮抗剂的组合产品
JOP20190080A1 (ar) 2016-10-14 2019-04-11 Bayer Pharma AG مركبات مشتقة من 6-(1h-بيرازول-1-يل) بيريميدين-4- أمين مستبدل واستخداماتها
US10927098B2 (en) 2016-10-20 2021-02-23 Bayer Pharma Aktiengesellschaft Hydroxyalkyl-substituted triazole derivatives and uses thereof
SG10202104865UA (en) 2016-11-08 2021-06-29 Cyclerion Therapeutics Inc Treatment of cns diseases with sgc stimulators
US11180493B2 (en) 2016-11-08 2021-11-23 Cyclerion Therapeutics, Inc. SGC stimulators
EP3554488A2 (en) 2016-12-13 2019-10-23 Cyclerion Therapeutics, Inc. Use of sgc stimulators for the treatment of esophageal motility disorders
JOP20190141A1 (ar) 2016-12-21 2019-06-12 Bayer Pharma AG أشكال جرعات صيدلية تحتوي على مثبطات لقناة task-1 و task-3 واستخدامها في معالجة اضطراب تنفسي
JOP20190148A1 (ar) 2016-12-21 2019-06-18 Bayer Pharma AG أشكال جرعات صيدلية تحتوي على مثبطات قنوات task-1 و task-3 واستخدامها لمعالجة الاضطرابات التنفسية
EP3338803A1 (de) 2016-12-21 2018-06-27 Bayer Pharma Aktiengesellschaft Pharmazeutische darreichungsformen enthaltend inhibitoren von task-1 und task-3 kanälen und deren verwendung für die therapie von atemstörungen
EP3338764A1 (de) 2016-12-21 2018-06-27 Bayer Pharma Aktiengesellschaft Pharmazeutische darreichungsformen enthaltend inhibitoren von task-1 und task-3 kanälen und deren verwendung für die therapie von atemstörungen
PE20191716A1 (es) 2017-02-08 2019-12-05 Bristol Myers Squibb Co Polipeptidos de relaxina modificada que comprenden un mejorador farmacocinetico y sus usos
WO2018153899A1 (de) 2017-02-22 2018-08-30 Bayer Pharma Aktiengesellschaft Selektive partielle adenosin a1 rezeptor-agonisten in kombination mit stimulatoren und/oder aktivatoren der löslichen guanylatcyclase (sgc)
TWI770157B (zh) 2017-04-10 2022-07-11 德商拜耳廠股份有限公司 經取代之n-芳基乙基-2-胺基喹啉-4-甲醯胺及其用途
AU2018251758B2 (en) 2017-04-10 2021-11-18 Bayer Aktiengesellschaft Substituted N-arylethyl-2-arylquinoline-4-carboxamides and use thereof
WO2018227427A1 (en) 2017-06-14 2018-12-20 Bayer Aktiengesellschaft Substituted bridged diazepane derivatives and use thereof
JOP20190284A1 (ar) 2017-06-14 2019-12-11 Bayer Pharma AG مركبات إيميدازوبيريميدين مستبدلة بديازا ثنائي الحلقة واستخدامها للمعالجة من اضطرابات التنفس
WO2019081303A1 (en) 2017-10-24 2019-05-02 Bayer Pharma Aktiengesellschaft SUBSTITUTED TRIAZOLE DERIVATIVES AND USES THEREOF
WO2019081456A1 (en) 2017-10-24 2019-05-02 Bayer Aktiengesellschaft USE OF SGC ACTIVATORS AND STIMULATORS COMPRISING A BETA2 SUBUNIT
EP3700897A1 (en) 2017-10-24 2020-09-02 Bayer Pharma Aktiengesellschaft Substituted triazole derivatives and uses thereof
EP3700896A1 (en) 2017-10-24 2020-09-02 Bayer Pharma Aktiengesellschaft Amine substituted triazole derivatives and uses thereof
WO2019081306A1 (en) 2017-10-24 2019-05-02 Bayer Pharma Aktiengesellschaft SUBSTITUTED TRIAZOLE DERIVATIVES AND USES THEREOF
WO2019081291A1 (en) 2017-10-24 2019-05-02 Bayer Aktiengesellschaft PRODRUGS OF SUBSTITUTED TRIAZOLE DERIVATIVES AND USES THEREOF
KR20200069361A (ko) 2017-10-24 2020-06-16 바이엘 악티엔게젤샤프트 치환된 트리아졸 유도체의 전구약물 및 그의 용도
JOP20200073A1 (ar) 2017-10-24 2020-04-29 Bayer Pharma AG مركبات أميد إيميدازوبيريدين تحمل بدائل واستخداماتها
CA3084308A1 (en) 2017-10-24 2019-05-02 Bayer Aktiengesellschaft Substituted triazole derivatives and uses thereof
CA3081775A1 (en) 2017-11-07 2019-05-16 Bayer Aktiengesellschaft Substituted 2,4-dihydro-3h-1,2,4-triazol-3-ones and use of same
EP3498298A1 (en) 2017-12-15 2019-06-19 Bayer AG The use of sgc stimulators and sgc activators alone or in combination with pde5 inhibitors for the treatment of bone disorders including osteogenesis imperfecta (oi)
MA51305A (fr) 2017-12-19 2020-10-28 Cyclerion Therapeutics Inc Stimulateurs de sgc
AU2019231724B2 (en) 2018-03-07 2024-06-27 Tisento Therapeutics Inc. Crystalline forms of an sGC stimulator
EP3553081A1 (en) 2018-04-12 2019-10-16 Bayer Aktiengesellschaft Atrial natriuretic peptide engrafted antibodies
EP3553079A1 (en) 2018-04-12 2019-10-16 Bayer Aktiengesellschaft C-type natriuretic peptide engrafted antibodies
EP3553082A1 (en) 2018-04-12 2019-10-16 Bayer Aktiengesellschaft Brain natriuretic peptide engrafted antibodies
WO2019211081A1 (en) 2018-04-30 2019-11-07 Bayer Aktiengesellschaft The use of sgc activators and sgc stimulators for the treatment of cognitive impairment
CA3100096A1 (en) 2018-05-15 2019-11-21 Bayer Aktiengesellschaft 1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization
EP3793559A1 (en) 2018-05-17 2021-03-24 Bayer Aktiengesellschaft Substituted dihydropyrazolo pyrazine carboxamide derivatives
US11508483B2 (en) 2018-05-30 2022-11-22 Adverio Pharma Gmbh Method of identifying a subgroup of patients suffering from dcSSc which benefits from a treatment with sGC stimulators and sGC activators in a higher degree than a control group
SG11202100092QA (en) 2018-07-11 2021-02-25 Cyclerion Therapeutics Inc USE OF sGC STIMULATORS FOR THE TREATMENT OF MITOCHONRIAL DISORDERS
GEP20247606B (en) 2018-11-27 2024-03-11 Bayer Ag Process for producing pharmaceutical dosage forms containing task-1 and task-3 channel inhibitors, and the use of same in breathing disorder therapy
CA3126778A1 (en) 2019-01-17 2020-07-23 Bayer Aktiengesellschaft Methods to determine whether a subject is suitable of being treated with an agonist of soluble guanylyl cyclase (sgc)
WO2020164008A1 (en) 2019-02-13 2020-08-20 Bayer Aktiengesellschaft Process for the preparation of porous microparticles
WO2020165031A1 (de) 2019-02-15 2020-08-20 Bayer Aktiengesellschaft Substituierte isochinolin-piperidinylmethanon-derivate
WO2020216669A1 (de) 2019-04-23 2020-10-29 Bayer Aktiengesellschaft Phenylsubstituierte imidazopyridinamide und ihre verwendung
EP3966226B1 (en) 2019-05-07 2025-12-24 Bayer Aktiengesellschaft Masp inhibitory compounds and uses thereof
EP3972599B1 (en) 2019-05-21 2025-10-22 Ardelyx, Inc. Combination for lowering serum phosphate in a patient
AU2020377470A1 (en) 2019-11-06 2022-05-26 Bayer Aktiengesellschaft Inhibitors of adrenoreceptor ADRAC2
WO2021094209A1 (en) 2019-11-12 2021-05-20 Bayer Aktiengesellschaft Substituted pyrrolo triazine carboxamide derivatives as prostaglandin ep3 receptor antagonists
WO2021094208A1 (en) 2019-11-12 2021-05-20 Bayer Aktiengesellschaft Substituted imidazo pyrimidine ep3 antagonists
WO2021094210A1 (en) 2019-11-12 2021-05-20 Bayer Aktiengesellschaft Substituted pyrazine carboxamide derivatives as prostaglandin ep3 receptor antagonists
EP3822265A1 (en) 2019-11-15 2021-05-19 Bayer AG Substituted hydantoinamides as adamts7 antagonists
EP3822268A1 (en) 2019-11-15 2021-05-19 Bayer Aktiengesellschaft Substituted hydantoinamides as adamts7 antagonists
WO2021167458A1 (en) 2020-02-21 2021-08-26 Universiteit Maastricht Use of a soluble guanylate cyclase (sgc) stimulator or of a combination of a sgc stimulator and an sgc activator for conditions wherein the heme group of sgc is oxidized or wherein sgc is deficient in heme
EP4110396A1 (en) 2020-02-26 2023-01-04 Universiteit Maastricht Therapeutic combination for the treatment of brain ischemia and said therapeutic combination for use in the treatment of brain ischemia
WO2021195403A1 (en) 2020-03-26 2021-09-30 Cyclerion Therapeutics, Inc. Deuterated sgc stimulators
WO2021202546A1 (en) 2020-03-31 2021-10-07 Cyclerion Therapeutics, Inc. Early drug interventions to reduce covid-19 related respiratory distress, need for ventilator assistance and death
WO2022112213A1 (en) 2020-11-30 2022-06-02 Bayer Aktiengesellschaft Crystalline forms of 3-[[3-(4-chlorophenyl)-5-oxo-4-((2s)-3,3,3-trifluoro- 2-hydroxypropyl)-4,5-dihydro-1h-1,2,4-triazol-1-yl]methyl]-1-[3- (trifluoromethyl)pyridin-2-yl]-1h-1,2,4-triazole-5-carboxamide
EP4011874A1 (en) 2020-12-10 2022-06-15 Bayer Aktiengesellschaft Substituted pyrazolo piperidine carboxylic acids
CN116829545A (zh) 2020-12-10 2023-09-29 拜耳公司 取代的吡唑基哌啶羧酸
MX2023006903A (es) 2020-12-10 2023-06-26 Bayer Ag Acidos pirazol piperidin carboxilicos sustituidos.
JP7458683B2 (ja) 2020-12-10 2024-04-01 バイエル・アクチエンゲゼルシヤフト 眼科疾患の治療のためのｓＧＣ活性化剤の使用
EP4011873A1 (en) 2020-12-10 2022-06-15 Bayer Aktiengesellschaft Substituted pyrazolo piperidine carboxylic acids
AU2022261862A1 (en) 2021-04-20 2023-11-30 Tisento Therapeutics Inc. Sgc stimulators
TW202308634A (zh) 2021-04-20 2023-03-01 美商賽克瑞恩醫療公司 使用sGC刺激劑之CNS疾病治療
WO2022265984A1 (en) 2021-06-14 2022-12-22 Curtails Llc Use of nep inhibitors for the treatment of gastrointestinal sphincter disorders
US20240342188A1 (en) 2021-08-11 2024-10-17 Curtails Llc Use of NEP Inhibitors for the Treatment of Laminitis
CA3244893A1 (en) 2021-12-29 2023-07-06 Bayer Aktiengesellschaft PROCESS FOR PREPARING (5S)-{[2-(4-CARBOXYPHENYL)ETHYL] |2-(2-{|3-CHLORO-4'-(TRIFLUOROMETHYL)BIPHENYL-4-YL]METHOXY}PHENYL)ETHYL]AMINOL-5,6,7,8-TETRAHYDROQUINOLINE-2-CARBOXYLIC AND ITS CRYSTALLINE FORMS FOR USE AS A PHARMACEUTICALLY ACTIVE COMPOUND
EP4456896A1 (en) 2021-12-29 2024-11-06 Bayer Aktiengesellschaft Treatment of cardiopulmonary disorders
CA3244896A1 (en) 2021-12-29 2023-07-06 Bayer Aktiengesellschaft Pharmaceutical dry powder inhalation formulation
EP4536205A1 (en) 2022-06-09 2025-04-16 Bayer Aktiengesellschaft Soluble guanylate cyclase activators for use in the treatment of heart failure with preserved ejection fraction in women
JP2025536343A (ja) 2022-10-18 2025-11-05 ティセント セラピューティクス インコーポレーテッド ピリミジンｓｇｃ刺激剤
EP4605080A1 (en) 2022-10-18 2025-08-27 Tisento Therapeutics Inc. Treatment of mitochondrial diseases with sgc stimulators
WO2025068514A1 (en) 2023-09-28 2025-04-03 Bayer Aktiengesellschaft Substituted heterocyclic carboxamindes and use thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1593837A1 (de) * 1967-06-29 1970-10-29 Degussa Verfahren zur Herstellung von neuen Aminoketonen
DE2702600A1 (de) * 1977-01-22 1978-07-27 Thomae Gmbh Dr K Neue aminoalkoxyphenyl-derivate
US4450173A (en) * 1980-11-28 1984-05-22 American Hospital Supply Corporation Compounds and method for treatment or prophylaxis of cardiac disorders
EP0053434B1 (en) 1980-11-28 1986-08-27 American Hospital Supply Corporation Compounds and method for treatment or prophylaxis of cardiac disorders
EP0079872B1 (en) * 1981-11-17 1985-03-20 KabiVitrum AB Antifibrinolytically active compounds
EP0099707B1 (en) 1982-07-16 1986-12-10 Beecham Group Plc 2-aminoethyl ether derivatives, processes for their preparation and pharmaceutical compositions containing them
GB2218416A (en) 1988-05-13 1989-11-15 Bayer Ag Leukotriene disease antagonists
GB8813185D0 (en) * 1988-06-03 1988-07-06 Wyeth John & Brother Ltd New method & amines used therein
US5154837A (en) * 1990-12-03 1992-10-13 Jones A Alan Flexible form
AU2238192A (en) 1991-06-27 1993-01-25 Du Pont Merck Pharmaceutical Company, The Modified peptides transportable into the central nervous system
ATE180468T1 (de) * 1993-12-27 1999-06-15 Eisai Co Ltd Anthranilsäure derivate
ID22176A (id) 1996-10-14 1999-09-09 Bayer Ag Turunan pirazola tersubstitusi-heterosiklilmetil yang baru
DE19642255A1 (de) 1996-10-14 1998-04-16 Bayer Ag Verwendung von 1-Benzyl-3-(substituierten-hetaryl) -kondensierten Pyrazol-Derivaten
DE19649460A1 (de) * 1996-11-26 1998-05-28 Bayer Ag Neue substituierte Pyrazolderivate
RU2123046C1 (ru) * 1997-12-26 1998-12-10 Биологический факультет МГУ им.М.В.Ломоносова Донор оксида азота и активатор растворимой формы гуанилатциклазы
US7501538B2 (en) * 2003-08-08 2009-03-10 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions and methods of use

Also Published As

Publication number Publication date
DK1216225T3 (da) 2005-11-07
NO327998B1 (no) 2009-11-09
PE20010637A1 (es) 2001-07-12
RU2280025C2 (ru) 2006-07-20
ATE299134T1 (de) 2005-07-15
IL148134A0 (en) 2002-09-12
HRP20020307B1 (hr) 2009-02-28
JP2003509401A (ja) 2003-03-11
JP4456312B2 (ja) 2010-04-28
AR033346A1 (es) 2003-12-17
US20100317854A1 (en) 2010-12-16
EE200200130A (et) 2003-04-15
BR0014179A (pt) 2002-05-21
BG65834B1 (bg) 2010-02-26
ZA200201299B (en) 2003-05-28
CZ2002918A3 (cs) 2002-09-11
EP1216225B1 (de) 2005-07-06
IL148134A (en) 2008-11-26
WO2001019780A2 (de) 2001-03-22
ES2244466T3 (es) 2005-12-16
CA2387107A1 (en) 2001-03-22
RU2280025C9 (ru) 2008-06-20
AU7000900A (en) 2001-04-17
US20090203906A1 (en) 2009-08-13
CO5221052A1 (es) 2002-11-28
DE19943635A1 (de) 2001-03-15
EE05194B1 (et) 2009-08-17
AU767750B2 (en) 2003-11-20
TR200200649T2 (tr) 2002-07-22
CA2387107C (en) 2011-04-12
PL353790A1 (en) 2003-12-01
EP1216225A2 (de) 2002-06-26
RU2002109814A (ru) 2004-02-20
TWI225045B (en) 2004-12-11
HK1053638A1 (zh) 2003-10-31
PT1216225E (pt) 2005-11-30
JP2010077153A (ja) 2010-04-08
WO2001019780A3 (de) 2001-09-07
NO20021226D0 (no) 2002-03-12
KR100715380B1 (ko) 2007-05-07
NO20021226L (no) 2002-05-03
MY128659A (en) 2007-02-28
UY26332A1 (es) 2001-04-30
SV2002000169A (es) 2002-01-15
HRP20020307A2 (en) 2004-02-29
DE50010677D1 (de) 2005-08-11
UA74346C2 (uk) 2005-12-15
CZ302250B6 (cs) 2011-01-12
HK1053638B (zh) 2009-05-08
HUP0203418A2 (hu) 2003-02-28
MXPA02002651A (es) 2002-10-23
SK287368B6 (sk) 2010-08-09
CN1390196A (zh) 2003-01-08
US20060094769A1 (en) 2006-05-04
KR20020025263A (ko) 2002-04-03
PL206256B1 (pl) 2010-07-30
NZ517709A (en) 2004-05-28
MA25875A1 (fr) 2003-10-01
CN100390135C (zh) 2008-05-28
US7781470B2 (en) 2010-08-24
US7517896B2 (en) 2009-04-14
US7087644B1 (en) 2006-08-08
HUP0203418A3 (en) 2003-04-28
SK3382002A3 (en) 2002-07-02
BG106494A (bg) 2003-03-31

Similar Documents

Publication Publication Date Title
CU23105A3 (es) DERIVADOS NOVEDOSOS DEL áCIDO AMINODICARBOXILICO CON PROPIEDADES FARMACéUTICAS
BR0312513A (pt) Derivados de glicosìdeo de tiofeno, processos para a produção dos mesmos, medicamentos que contêm esses compostos e uso dos mesmos
BR0014178A (pt) Derivados de ácido dicarboxìlico com propriedades farmacêuticas
BR122019010008B8 (pt) derivados de pirimidina, seu uso, e composição e combinação farmacêuticas
ECSP034460A (es) Nuevos compuestos heterociclicos, su preparacion y su utilizacion como medicamentos, en especial como antibacterianos
BRPI0413452A (pt) composto, composição farmacêutica, kit, artigo de fabricação, e, métodos de inibir dpp-iv, terapêutico e de tratar um estado de doença, cáncer, distúrbios autoimunes, uma condição einfecção por hiv
CU23208A3 (es) Oxazolidinonas sustituidas y su uso en el campo de la coagulacion sanguinea
PA8635201A1 (es) Uso de derivados quinolina sustituidos para el tratamiento de enfermedades micobacterianas resistentes a los farmacos
ECSP045193A (es) "nuevos compuestos heterociclicos, activos como inhibidores de beta-lactamasas"
PA8547701A1 (es) Nucleosidos 4 substituidos.
CO6300957A2 (es) Derivados de imidazo -[1,2,b]-piridazina para el tratamiento de enfermedad mediada por cinasa de tirosina c-met
UY26782A1 (es) Derivados del benzotiazol
AR025444A1 (es) Derivados de sulfonil-carboxamida, procedimientos para su preparacion y su utilizacion como medicamentos
BR0112589A (pt) Derivados de heteroarila e sua aplicação como medicamento
UY30438A1 (es) Derivados n-sustituidos de 5-halo-4-[2-alquil-1-sustituidos-1h-imidazol-5-il]pirimidin-2-amina, composiciones-procesos para su preparacion y usos
ES2187300B1 (es) Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos.
BRPI0416989A (pt) derivados aminopirazole como inibidores gsk-3
DK1641454T3 (da) Pyrazolo[3,4-B]pyridin-6-oner som GSK-3-hæmmere
UY32829A (es) Derivados de 3-heteroaril-metil-imidazo-[1,2-b]-pirididazin - 6 -ilo
UY28356A1 (es) Derivados de benzimidazol, composiciones que los contienen, preparaciones de los mismos y sus usos
MXPA05006889A (es) Compuestos aromaticos como agentes anti-inflamatorios, inmunomoduladores y anti-proliferativos.
UY28357A1 (es) Derivados de benzimidazol, composiciones que los contienen, preparación de los mismos y sus usos
AR001769A1 (es) Benzamida enterocinética composiciones farmacéuticas que las contienen procedimiento para la preparación de dichas composiciones farmacéuticas el uso de dichos compuestos para la manufactura de medicamentos y un procedimiento para su preparación
BRPI0416188A (pt) formulações de medicamentos que contêm aromatizante, com propriedades farmacêuticas aperfeiçoadas
BR0110255A (pt) Cromenilmetil pirimidinadiaminas como agentes antibacterianos

Legal Events

Date Code Title Description
FD Lapse (for not paying fees)